Lidan Yi

473 total citations
29 papers, 350 citations indexed

About

Lidan Yi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Lidan Yi has authored 29 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Economics and Econometrics. Recurrent topics in Lidan Yi's work include Cancer Immunotherapy and Biomarkers (9 papers), Economic and Financial Impacts of Cancer (7 papers) and Gastric Cancer Management and Outcomes (7 papers). Lidan Yi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Economic and Financial Impacts of Cancer (7 papers) and Gastric Cancer Management and Outcomes (7 papers). Lidan Yi collaborates with scholars based in China, Australia and Hong Kong. Lidan Yi's co-authors include Chongqing Tan, Xiaohui Zeng, Xiaomin Wan, Liubao Peng, Xia Luo, Qiao Liu, Sini Li, Peng Ye, Liting Wang and Jianhe Li and has published in prestigious journals such as PLoS ONE, Frontiers in Immunology and Frontiers in Pharmacology.

In The Last Decade

Lidan Yi

29 papers receiving 344 citations

Peers

Lidan Yi
Qiao Liu China
Robert Hettle United Kingdom
Jennifer M. Suga United States
Vishal Navani Canada
Sandip Ganguly India
Dayssy A. Diaz United States
Y.J. Ko Canada
Edith Mitchell United States
Christina Canil Canada
Marcela Santos Cavalcanti United States
Qiao Liu China
Lidan Yi
Citations per year, relative to Lidan Yi Lidan Yi (= 1×) peers Qiao Liu

Countries citing papers authored by Lidan Yi

Since Specialization
Citations

This map shows the geographic impact of Lidan Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lidan Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lidan Yi more than expected).

Fields of papers citing papers by Lidan Yi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lidan Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lidan Yi. The network helps show where Lidan Yi may publish in the future.

Co-authorship network of co-authors of Lidan Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Lidan Yi. A scholar is included among the top collaborators of Lidan Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lidan Yi. Lidan Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yi, Lidan, Zhen Zhou, Xiaohui Zeng, Chongqing Tan, & Qiao Liu. (2024). First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis. Frontiers in Immunology. 15. 1408928–1408928. 5 indexed citations
2.
3.
Ye, Peng, Liting Wang, Liubao Peng, et al.. (2023). Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States. Clinical Therapeutics. 45(10). 965–972. 3 indexed citations
4.
Tan, Chongqing, Xia Luo, Zhen Zhou, et al.. (2023). Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis. Journal of Infection and Public Health. 16(6). 893–900. 11 indexed citations
5.
6.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2022). Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology. 13. 778505–778505. 19 indexed citations
7.
Liu, Qiao, Zhen Zhou, Xia Luo, et al.. (2022). Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%. Frontiers in Pharmacology. 12. 803626–803626. 5 indexed citations
8.
Liu, Qiao, Xia Luo, Zhen Zhou, et al.. (2021). PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China. Frontiers in Oncology. 11. 745493–745493. 3 indexed citations
9.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers in Oncology. 11. 743765–743765. 4 indexed citations
10.
Tan, Chongqing, Xia Luo, Sini Li, et al.. (2021). Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. Clinical Rheumatology. 41(1). 63–73. 4 indexed citations
11.
Yi, Lidan, Sini Li, Chongqing Tan, et al.. (2021). Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer. Advances in Therapy. 38(6). 3399–3408. 11 indexed citations
12.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer. Advances in Therapy. 38(7). 3962–3972. 12 indexed citations
13.
Zeng, Xiaohui, Qiao Liu, Peng Ye, et al.. (2021). Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. Advances in Therapy. 38(5). 2379–2390. 1 indexed citations
14.
Ye, Peng, Liubao Peng, Qiao Liu, et al.. (2021). Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States. Advances in Therapy. 38(12). 5710–5720. 8 indexed citations
15.
Li, Sini, Liubao Peng, Chongqing Tan, et al.. (2020). Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS ONE. 15(5). e0232240–e0232240. 22 indexed citations
16.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2020). Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 10(11). e040691–e040691. 8 indexed citations
17.
Ye, Peng, Chongqing Tan, Xiaomin Wan, et al.. (2019). Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Advances in Therapy. 36(11). 3047–3058. 6 indexed citations
18.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2019). Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis. Clinical Drug Investigation. 40(2). 129–137. 40 indexed citations
19.
Zeng, Xiaohui, Jianhe Li, Liubao Peng, et al.. (2014). Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis. PLoS ONE. 9(2). e88881–e88881. 23 indexed citations
20.
Tan, Chongqing, Liubao Peng, Xiaohui Zeng, et al.. (2013). Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China. PLoS ONE. 8(12). e83396–e83396. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiao Liu Breakdown of academic impact, for papers by Robert Hettle Breakdown of academic impact, for papers by Jennifer M. Suga Breakdown of academic impact, for papers by Vishal Navani Breakdown of academic impact, for papers by Sandip Ganguly Breakdown of academic impact, for papers by Dayssy A. Diaz Breakdown of academic impact, for papers by Y.J. Ko Breakdown of academic impact, for papers by Edith Mitchell Breakdown of academic impact, for papers by Christina Canil Breakdown of academic impact, for papers by Marcela Santos Cavalcanti
Rankless by CCL
2026